Cadonilimab is a humanized bsAb that binds concurrently to PD-1 and CTLA-4 with high affinity on tumor-infiltrating lymphocytes (TILs), thereby enhancing antitumor efficacy and also safety [82]. Here, CTLA4 is linked to neoplasm.